Last updated: February 19, 2026
What is SOLIQUA 100/33 and Its Therapeutic Indication?
SOLIQUA 100/33 (insulin glargine and lixisenatide) is a fixed-ratio combination injectable drug developed by Sanofi. It is indicated for the treatment of adults with type 2 diabetes mellitus who require basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for glycemic control. The drug combines 100 units/mL of insulin glargine 300 (a long-acting basal insulin) with 33 mcg/mL of lixisenatide (a prandial GLP-1 RA) in a single pen device.
What is the Current Market Landscape for Combination Diabetes Therapies?
The market for diabetes medications, particularly those for type 2 diabetes, is characterized by a growing demand for combination therapies that offer improved efficacy, convenience, and patient adherence. SOLIQUA 100/33 competes within a segment that includes other fixed-ratio injectable combinations and co-formulated oral medications.
Key competitors and their therapeutic classes include:
-
Basal Insulin and GLP-1 RA Combinations:
- XULTOPHY 100/3.6 (insulin degludec and liraglutide) – Novo Nordisk. Approved in Europe and other regions, not in the US.
- IGLARLIX (insulin glargine and lixisenatide) – Sanofi. This is the same molecule as SOLIQUA 100/33, but marketed under a different name in some territories.
-
Other Combination Injectables:
- Dual GIP/GLP-1 Receptor Agonists: Tirzepatide (Mounjaro, Zepbound) by Eli Lilly and Company, a dual GIP and GLP-1 receptor agonist, has demonstrated significant efficacy in glycemic control and weight loss, positioning it as a major competitor. While not a direct fixed-ratio insulin combination, its broad efficacy profile impacts the market for all diabetes therapies.
- Insulin-only combinations (e.g., faster-acting insulins with basal insulins).
-
Oral Combination Therapies:
- Metformin with DPP-4 inhibitors (e.g., sitagliptin, saxagliptin).
- Metformin with SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin).
- Metformin with sulfonylureas.
The market is driven by an increasing prevalence of type 2 diabetes globally, a greater understanding of the benefits of dual mechanisms of action for improved glycemic control and cardiovascular outcomes, and a patient preference for simpler dosing regimens.
What are the Patent Expirations and Exclusivity Periods for SOLIQUA 100/33?
The patent landscape for SOLIQUA 100/33 is complex, involving patents covering the compound, formulations, and methods of use. As of late 2023, key patents are nearing expiration or have expired, opening avenues for generic or biosimilar competition.
-
US Patent Expirations: While specific patent numbers and their exact expiry dates are subject to ongoing legal challenges and continuations, the foundational patents for the active pharmaceutical ingredients (insulin glargine and lixisenatide) have either expired or are nearing expiration in major markets. The combination product itself is protected by a suite of patents.
- Key patents related to insulin glargine have expired.
- Patents covering lixisenatide are also in various stages of expiration.
- Patents specifically protecting the combination formulation and its manufacturing processes are crucial for extended market exclusivity. For example, US Patent No. 9,089,612, pertaining to lixisenatide and its use, has an expiry date of October 28, 2030, but this can be subject to patent term extensions. However, other related patents or formulation patents may expire earlier or later.
- Orphan Drug Exclusivity: Not applicable for SOLIQUA 100/33 as it is not designated as an orphan drug.
- New Chemical Entity (NCE) Exclusivity: SOLIQUA 100/33, as a fixed-dose combination of previously approved active ingredients, generally does not qualify for NCE exclusivity in the US. However, the FDA may grant exclusivity for a combination product if it demonstrates significant new clinical benefits compared to the individual components. This was not a primary basis for exclusivity for SOLIQUA 100/33.
-
European Patent Expirations: Similar to the US, European Patent Office (EPO) protection for the individual components has largely expired or is nearing expiry. Patents protecting the specific combination formulation and its therapeutic advantages will dictate the later stages of market exclusivity. Supplementary Protection Certificates (SPCs) in Europe extend patent protection beyond the expiry date of the basic patent, typically up to five years, for medicinal products. The expiry of these SPCs for SOLIQUA 100/33 is a critical factor for market entry of generics.
Impact of Patent Expiration: The expiry of these patents is expected to allow for the introduction of generic or biosimilar versions of SOLIQUA 100/33, potentially leading to price erosion and increased competition. The timing of these expirations, combined with the potential for litigation and market entry strategies by biosimilar manufacturers, will shape the competitive landscape.
What are the Sales Performance and Financial Projections for SOLIQUA 100/33?
Sanofi's sales performance for SOLIQUA 100/33 has shown moderate growth, influenced by market adoption, competition, and the broader commercial strategy for its diabetes portfolio.
| Year |
Net Sales (USD Millions) |
Growth Rate (%) |
Source |
| 2021 |
395 |
N/A |
Sanofi Annual Report [1] |
| 2022 |
430 |
8.86 |
Sanofi Annual Report [2] |
| 2023 (YTD) |
210 (Q1-Q3) |
N/A |
Sanofi Quarterly Reports [3] |
Note: 2023 figures are for the first three quarters and do not represent full-year performance.
Factors Influencing Sales:
- Market Penetration: SOLIQUA 100/33 targets a specific patient population within type 2 diabetes management, and its uptake is dependent on physician prescribing patterns and patient access.
- Competitive Pressure: The emergence of highly effective treatments like tirzepatide and the ongoing presence of other insulin and GLP-1 RA therapies create a competitive environment.
- Geographic Performance: Sales performance can vary significantly by region due to differing market dynamics, regulatory approvals, and reimbursement policies.
- Product Lifecycle: As a product nearing its patent cliff, future sales projections are heavily influenced by the anticipated impact of generic competition.
Financial Projections: Precise, publicly disclosed financial projections for SOLIQUA 100/33 beyond the immediate future are not typically provided by Sanofi due to competitive sensitivities. However, industry analyses suggest that sales are likely to face pressure post-patent expiry. The company's strategy will involve maximizing remaining exclusivity and managing the transition to generic competition.
What is the Regulatory Status and Reimbursement Landscape?
The regulatory and reimbursement landscape significantly impacts the commercial viability and market access of SOLIQUA 100/33.
-
Regulatory Approvals:
- United States: Approved by the U.S. Food and Drug Administration (FDA) in November 2016.
- European Union: Approved by the European Medicines Agency (EMA) in February 2015 (as IGLARLIX).
- Other Markets: Approved in various other countries, including Japan, Canada, and Australia.
-
Reimbursement:
- Payer Coverage: Reimbursement for SOLIQUA 100/33 is determined by payers (insurance companies, government health programs) based on clinical guidelines, cost-effectiveness, and formulary placement.
- Formulary Status: The drug's position on formularies can influence physician prescribing and patient out-of-pocket costs. Preferred formulary status generally leads to better access.
- Prior Authorization and Step Therapy: Some payers may require prior authorization or step-therapy protocols, necessitating that patients first try other diabetes medications before SOLIQUA 100/33 is covered.
- Affordability Programs: Sanofi offers patient assistance programs to help eligible individuals with out-of-pocket costs for SOLIQUA 100/33, mitigating some of the financial barriers to access.
Impact of Biosimilar/Generic Entry: The entry of biosimilar or generic versions will likely lead to price negotiations with payers and a potential shift in reimbursement strategies to accommodate lower-cost alternatives. Payers may increasingly favor biosimil options, impacting the market share and pricing power of the originator product.
What are the Key Competitive Threats and Market Opportunities?
The market for SOLIQUA 100/33 faces both significant competitive threats and discernible market opportunities.
Competitive Threats
- Emergence of Highly Effective Novel Agents: Tirzepatide (Mounjaro/Zepbound) represents a substantial competitive threat due to its superior efficacy in glycemic control and weight loss, potentially drawing market share away from all existing diabetes therapies, including combination insulins and GLP-1 RAs.
- Patent Expirations and Generic/Biosimilar Entry: The impending expiration of key patents will pave the way for the introduction of lower-cost generic and biosimilar alternatives, directly impacting SOLIQUA 100/33's market share and pricing power.
- Advancements in Other Diabetes Treatment Modalities: Continued innovation in oral medications, including SGLT2 inhibitors and DPP-4 inhibitors, as well as other injectable therapies with different mechanisms of action, provides physicians and patients with a diverse range of treatment options.
- Shifting Treatment Paradigms: A growing emphasis on non-glycemic benefits, such as weight loss and cardiovascular outcome improvements, may favor newer agents that demonstrably deliver these benefits more effectively than older insulin-based combinations.
Market Opportunities
- Established Patient Population: SOLIQUA 100/33 targets a well-defined segment of type 2 diabetes patients who require both basal insulin and a GLP-1 RA. Physicians familiar with the individual components may continue to prescribe the combination for established patients.
- Convenience of Fixed-Ratio Dosing: The single-pen delivery system offers a convenience factor, simplifying dosing regimens and potentially improving adherence for patients managing multiple comorbidities and medications. This convenience is a sustained value proposition.
- Potential for Combination with Other Drug Classes: While not currently marketed as such, future research or strategic partnerships could explore co-formulating SOLIQUA 100/33 with other anti-diabetic agents (e.g., SGLT2 inhibitors) to further enhance treatment efficacy and patient convenience, though this would likely require new patent protection and regulatory pathways.
- Emerging Markets: Expansion into emerging markets where access to novel, high-cost therapies might be limited presents an opportunity for SOLIQUA 100/33, provided pricing and regulatory hurdles can be navigated. The fixed-ratio combination offers a cost-effective solution for achieving dual-action therapy.
What is the Future Outlook for SOLIQUA 100/33?
The future outlook for SOLIQUA 100/33 is largely defined by its position in the market as key patents approach expiration.
- Near-Term (1-3 years): The product will likely maintain a stable, albeit mature, market presence. Sales may continue to grow moderately as physicians utilize the convenience and established efficacy for appropriate patient segments. Sanofi will focus on maximizing remaining market exclusivity and supporting adherence.
- Mid-Term (3-5 years): The anticipated entry of generic or biosimilar competitors will significantly disrupt the market. Expect a marked decline in market share and pricing power for SOLIQUA 100/33 as payers and patients shift to more cost-effective alternatives. Sanofi's strategy will involve managing this transition, potentially through authorized generics or brand loyalty programs.
- Long-Term (5+ years): The market presence of SOLIQUA 100/33 will likely be minimal, with generics and biosimilars dominating its therapeutic niche. Its commercial trajectory will be largely determined by the success and cost-effectiveness of these follow-on products.
The competitive landscape is dynamic, with continuous innovation in diabetes management. The strategic importance of SOLIQUA 100/33 within Sanofi's broader diabetes portfolio will also influence resource allocation and commercial support in the face of evolving market demands and therapeutic advancements.
Key Takeaways
- SOLIQUA 100/33, a fixed-ratio combination of insulin glargine and lixisenatide, targets adults with type 2 diabetes requiring basal insulin and GLP-1 RA therapy.
- The product faces a competitive market populated by other dual-acting injectables and emerging novel agents like tirzepatide.
- Key patents protecting SOLIQUA 100/33 are nearing expiration, signaling an imminent threat from generic and biosimilar competition.
- Sanofi reported moderate sales growth for SOLIQUA 100/33, with 2022 net sales reaching $430 million.
- Regulatory approvals are established in major markets, but reimbursement is subject to payer policies and formulary placement.
- The future outlook is characterized by expected market erosion post-patent expiry, with generics and biosimilars poised to capture market share.
FAQs
-
When is the primary patent for SOLIQUA 100/33 expected to expire in the United States?
While specific patent expiry dates are complex and subject to litigation and extensions, foundational patents related to the individual active ingredients have largely expired or are nearing expiry, with key combination and formulation patents providing extended protection potentially through the early to mid-2030s, subject to ongoing legal challenges.
-
What is the main competitive advantage of SOLIQUA 100/33 over individual injectable therapies?
The primary advantage is the convenience of a fixed-ratio, once-daily injection combining a basal insulin with a GLP-1 receptor agonist in a single pen device, simplifying treatment regimens and potentially improving patient adherence.
-
How will the introduction of tirzepatide impact the market for SOLIQUA 100/33?
Tirzepatide, with its superior efficacy in glycemic control and weight loss, poses a significant competitive threat by potentially drawing patients and market share from existing therapies, including SOLIQUA 100/33, particularly among patients prioritizing these outcomes.
-
Are there any biosimilar or generic versions of SOLIQUA 100/33 currently approved in major markets?
As of late 2023, there are no approved biosimilar or generic versions of SOLIQUA 100/33 in the United States or the European Union. However, the landscape is expected to change as patent protections expire.
-
What is Sanofi's strategy for managing the market transition as SOLIQUA 100/33 approaches its patent cliff?
Sanofi's strategy typically involves maximizing sales during the period of market exclusivity, exploring authorized generics if feasible, and focusing on lifecycle management and the development of new therapeutic agents to offset future revenue declines.
Citations
[1] Sanofi. (2022). 2021 Annual Report. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reports
[2] Sanofi. (2023). 2022 Annual Report. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reports
[3] Sanofi. (2023). Q3 2023 Results. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reports
